Trending With Impact: Novel KEAP1/NRF2 Target Gene Regulating Ferroptosis and Radioresistance in Lung Cancers



October 26, 2022

  • Share
  • Oncotarget published this trending research perspective in Volume 13, entitled, "FSP1, a novel KEAP1/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers" by researchers from The Institute of Molecular and Translational Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an 710049, China; Department of Thoracic Surgery, Ruyang People’s Hospital, Luoyang 471200, China; Shaanxi Stem Cell Application Engineering Research Center, Shaanxi Jiuzhou Biomedical Science and Technology Group, Xi’an 710065, China; Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China. DOI - Correspondence to - Yilei Zhang - Abstract In the study of "A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers" which was published earlier in Nature Communications, the authors have identified a novel KEAP1/NRF2 target gene, FSP1, and demonstrated that FSP1 plays an essential role in NRF2-mediated ferroptosis resistance and radioresistance in KEAP1-deficient lung cancer cells. Currently, many NRF2 target genes have been found to participate in the regulation of ferroptosis, and exactly which one plays a dominant role seems unclear. This study proposes that FSP1 is the key effector in NRF2-mediated ferroptosis resistance and radioresistance in KEAP-deficient lung cancer cells, as we discussed in the manuscript. Sign up for free Altmetric alerts about this article - Keywords - KEAP1/NRF2, lung cancer, ferroptosis, radioresistance, therapy About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit and connect with us: SoundCloud - Facebook - Twitter - Instagram - YouTube - LinkedIn - Pinterest - Reddit - Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

    Cancer ResearchCell ScienceGenomicsImmunology

    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.